Kenvue Inc. (KVUE)

NYSE: KVUE · Real-Time Price · USD
21.65
+0.20 (0.93%)
At close: Jun 16, 2025, 4:00 PM
21.66
+0.01 (0.05%)
After-hours: Jun 16, 2025, 4:27 PM EDT
0.93%
Market Cap 41.57B
Revenue (ttm) 15.30B
Net Income (ttm) 1.06B
Shares Out 1.92B
EPS (ttm) 0.55
PE Ratio 39.26
Forward PE 18.64
Dividend $0.82 (3.79%)
Ex-Dividend Date May 14, 2025
Volume 16,315,093
Open 21.65
Previous Close 21.45
Day's Range 21.44 - 22.03
52-Week Range 17.67 - 25.17
Beta 0.93
Analysts Buy
Price Target 25.33 (+17.0%)
Earnings Date Aug 5, 2025

About KVUE

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]

IPO Date May 4, 2023
Employees 22,000
Stock Exchange NYSE
Ticker Symbol KVUE
Full Company Profile

Financial Performance

In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price forecast is $25.33, which is an increase of 17.00% from the latest price.

Price Target
$25.33
(17.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kenvue mulls sale of some skin health and beauty brands, sources say

Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment...

4 days ago - Reuters

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Kenvue Inc. and Encourages Long-Term Kenvue Investors to Contact the Firm - KVUE

PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Kenvue Inc. (NYSE:KVUE) on behalf of the com...

7 days ago - Accesswire

Kenvue: Steady Consumer Health Play; Initiate With 'Buy'

I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable resilience...

12 days ago - Seeking Alpha

June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs

Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, a...

Other symbols: ABBVABMADMADPBDXBKHCWT
12 days ago - Seeking Alpha

Benadryl, Band-Aid parent says tariffs and late allergy season are hurting its business

Kenvue Chief Executive Thibaut Mongon said the consumer continues to be under pressure.

13 days ago - Market Watch

Kenvue Debuts on Fortune 500 List

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for t...

14 days ago - Business Wire

Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank...

26 days ago - Business Wire

69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs

Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten...

27 days ago - Seeking Alpha

Moody's U.S. Debt Downgrade: Stocks Poised To Benefit

Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple an...

Other symbols: AALAAPLCCLCUKFGMGOOG
4 weeks ago - Seeking Alpha

Third Point details stakes in U.S. Steel, Kenvue in filing

Billionaire investor Daniel Loeb's hedge fund Third Point on Thursday detailed the size of its stakes in U.S. Steel and Kenvue , companies that shareholders hope will soon benefit from being bought by...

Other symbols: X
4 weeks ago - Reuters

Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. today announced its global efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative.

4 weeks ago - Business Wire

Kenvue: First Quarter A Sign Of Challenging Times, But Still A Solid Long-Term Play

Kenvue, a solid dividend-paying stock spun off from Johnson & Johnson, offers long-term upside despite current economic challenges and declining consumer sentiment. Recent earnings showed slight reven...

5 weeks ago - Seeking Alpha

Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript

Kenvue, Inc. (NYSE:KVUE) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Sofya Tsinis - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director P...

5 weeks ago - Seeking Alpha

Kenvue Boosts 2025 Sales Growth View

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the year, w...

5 weeks ago - WSJ

Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook

Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.

5 weeks ago - Investopedia

Kenvue first-quarter results beat estimates on strength in self care unit

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold medicines Tylenol and Benadryl helped offset a...

5 weeks ago - Reuters

Kenvue Reports First Quarter 2025 Results

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. “In Q1, our teams executed our plans while continuing to navigate ...

5 weeks ago - Business Wire

Kenvue Announces Chief Financial Officer Transition

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for ove...

5 weeks ago - Business Wire

Buy 3 "Safer" Dividend Kings Of 25 From May's 55

The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kin...

Other symbols: ADMADPBDXBKHCWTEDFRT
5 weeks ago - Seeking Alpha

Best Dividend Aristocrats For May 2025

Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...

6 weeks ago - Seeking Alpha

Loeb's Third Point builds stake in Band-Aid maker Kenvue

Billionaire investor Daniel Loeb's hedge fund Third Point is building a stake in Kenvue , sources familiar with the matter said on Friday, as some investors are pushing for strategic changes at the co...

7 weeks ago - Reuters

Kenvue to Announce First Quarter 2025 Results on May 8, 2025

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at...

7 weeks ago - Business Wire

Two Stocks To Consider During Market Unrest To Provide Income Stability

Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...

Other symbols: BUDJNJMOPMXLFXLKXLP
7 weeks ago - Seeking Alpha

Kenvue Declares Quarterly Cash Dividend

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend i...

2 months ago - Business Wire

Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue announced a five-year collaboration with Microsoft to transform digital operations through Artificial Intelligence (AI) technologies.

2 months ago - Business Wire